Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:ATP11A-NUCB2

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: ATP11A-NUCB2
	FusionPDB ID: 7717
	FusionGDB2.0 ID: 7717
		Hgene	Tgene
	Gene symbol	ATP11A	NUCB2
	Gene ID	23250	4925
	Gene name	ATPase phospholipid transporting 11A	nucleobindin 2
	Synonyms	ATPIH\|ATPIS	HEL-S-109\|NEFA
	Cytomap	13q34	11p15.1
	Type of gene	protein-coding	protein-coding
	Description	probable phospholipid-transporting ATPase IHATPase, class VI, type 11AP4-ATPase flippase complex alpha subunit ATP11Aphospholipid-translocating ATPasepotential phospholipid-transporting ATPase IH	nucleobindin-2DNA-binding protein NEFAepididymis secretory protein Li 109gastric cancer antigen Zg4nesfatin 1novel DNA binding/EF-hand/leucine zipper proteinnucleobinding 2prepronesfatin
	Modification date	20200313	20200329
	UniProtAcc	Q6ZP68 Main function of 5'-partner protein:	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000283558, ENST00000375630, ENST00000375645, ENST00000487903, ENST00000419448,	ENST00000532240, ENST00000323688, ENST00000458064, ENST00000529010,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	20 X 11 X 16=3520	11 X 12 X 4=528
	# samples	31	13
	** MAII score	log2(31/3520*10)=-3.50523530825042 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(13/528*10)=-2.02202630633 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: ATP11A [Title/Abstract] AND NUCB2 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: ATP11A [Title/Abstract] AND NUCB2 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	ATP11A(113344769)-NUCB2(17351673), # samples:1
Anticipated loss of major functional domain due to fusion event.	ATP11A-NUCB2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ATP11A-NUCB2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner

Gene

GO ID

GO term

PubMed ID

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr13:113344769/chr11:17351673)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across ATP11A (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across NUCB2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000283558	ATP11A	chr13	113344769	+	ENST00000323688	NUCB2	chr11	17351673	+	787	127	55	387	110
ENST00000283558	ATP11A	chr13	113344769	+	ENST00000529010	NUCB2	chr11	17351673	+	1180	127	55	387	110
ENST00000283558	ATP11A	chr13	113344769	+	ENST00000458064	NUCB2	chr11	17351673	+	419	127	55	387	110
ENST00000375630	ATP11A	chr13	113344769	+	ENST00000323688	NUCB2	chr11	17351673	+	787	127	55	387	110
ENST00000375630	ATP11A	chr13	113344769	+	ENST00000529010	NUCB2	chr11	17351673	+	1180	127	55	387	110
ENST00000375630	ATP11A	chr13	113344769	+	ENST00000458064	NUCB2	chr11	17351673	+	419	127	55	387	110
ENST00000487903	ATP11A	chr13	113344769	+	ENST00000323688	NUCB2	chr11	17351673	+	787	127	55	387	110
ENST00000487903	ATP11A	chr13	113344769	+	ENST00000529010	NUCB2	chr11	17351673	+	1180	127	55	387	110
ENST00000487903	ATP11A	chr13	113344769	+	ENST00000458064	NUCB2	chr11	17351673	+	419	127	55	387	110
ENST00000375645	ATP11A	chr13	113344769	+	ENST00000323688	NUCB2	chr11	17351673	+	787	127	55	387	110
ENST00000375645	ATP11A	chr13	113344769	+	ENST00000529010	NUCB2	chr11	17351673	+	1180	127	55	387	110
ENST00000375645	ATP11A	chr13	113344769	+	ENST00000458064	NUCB2	chr11	17351673	+	419	127	55	387	110

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000283558	ENST00000323688	ATP11A	chr13	113344769	+	NUCB2	chr11	17351673	+	0.027083145	0.9729169
ENST00000283558	ENST00000529010	ATP11A	chr13	113344769	+	NUCB2	chr11	17351673	+	0.010633406	0.9893666
ENST00000283558	ENST00000458064	ATP11A	chr13	113344769	+	NUCB2	chr11	17351673	+	0.024093596	0.9759064
ENST00000375630	ENST00000323688	ATP11A	chr13	113344769	+	NUCB2	chr11	17351673	+	0.027083145	0.9729169
ENST00000375630	ENST00000529010	ATP11A	chr13	113344769	+	NUCB2	chr11	17351673	+	0.010633406	0.9893666
ENST00000375630	ENST00000458064	ATP11A	chr13	113344769	+	NUCB2	chr11	17351673	+	0.024093596	0.9759064
ENST00000487903	ENST00000323688	ATP11A	chr13	113344769	+	NUCB2	chr11	17351673	+	0.027083145	0.9729169
ENST00000487903	ENST00000529010	ATP11A	chr13	113344769	+	NUCB2	chr11	17351673	+	0.010633406	0.9893666
ENST00000487903	ENST00000458064	ATP11A	chr13	113344769	+	NUCB2	chr11	17351673	+	0.024093596	0.9759064
ENST00000375645	ENST00000323688	ATP11A	chr13	113344769	+	NUCB2	chr11	17351673	+	0.027083145	0.9729169
ENST00000375645	ENST00000529010	ATP11A	chr13	113344769	+	NUCB2	chr11	17351673	+	0.010633406	0.9893666
ENST00000375645	ENST00000458064	ATP11A	chr13	113344769	+	NUCB2	chr11	17351673	+	0.024093596	0.9759064

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ATP11A-NUCB2

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
ATP11A	chr13	113344769	NUCB2	chr11	17351673	127	24	MDCSLVRTLVHRYTLDQQQFFTEEEL

Top

Potential FusionNeoAntigen Information of ATP11A-NUCB2 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

ATP11A-NUCB2_113344769_17351673.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B57:01	RTLVHRYTL	0.9955	0.9407	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:23	RYTLDQQQF	0.9931	0.7973	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B58:02	RTLVHRYTL	0.9926	0.7853	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B15:17	YTLDQQQFF	0.9918	0.889	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:25	RYTLDQQQF	0.991	0.878	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:20	RYTLDQQQF	0.9907	0.8734	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:15	RYTLDQQQF	0.9899	0.8758	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B15:16	YTLDQQQFF	0.9887	0.8083	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B35:08	YTLDQQQFF	0.9861	0.9199	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:31	RYTLDQQQF	0.9861	0.8779	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A32:13	RTLVHRYTL	0.983	0.6508	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B58:01	YTLDQQQFF	0.9797	0.8594	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B57:01	YTLDQQQFF	0.9791	0.9577	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B15:17	RTLVHRYTL	0.9748	0.7565	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B57:03	RTLVHRYTL	0.9747	0.924	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B58:02	YTLDQQQFF	0.9718	0.9293	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A30:08	RTLVHRYTL	0.9667	0.5634	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B15:16	RTLVHRYTL	0.965	0.66	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A23:05	RYTLDQQQF	0.9648	0.7375	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:17	RYTLDQQQF	0.9631	0.8394	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:10	RYTLDQQQF	0.9307	0.7946	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B57:03	YTLDQQQFF	0.9256	0.9869	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A23:04	RYTLDQQQF	0.91	0.699	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:15	YTLDQQQFF	0.8988	0.7658	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B53:01	YTLDQQQFF	0.8629	0.6522	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A36:03	YTLDQQQFF	0.8626	0.5562	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A31:08	RYTLDQQQF	0.862	0.8153	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:17	YTLDQQQFF	0.8581	0.7482	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A32:13	YTLDQQQFF	0.7864	0.984	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B46:01	YTLDQQQFF	0.7099	0.5629	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:14	RYTLDQQQF	0.6821	0.7801	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:14	YTLDQQQFF	0.6085	0.6896	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B13:01	YTLDQQQFF	0.1668	0.9918	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B27:05	HRYTLDQQQF	1	0.6557	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B27:04	HRYTLDQQQF	0.9999	0.7598	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B27:07	HRYTLDQQQF	0.9997	0.8365	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:23	RYTLDQQQFF	0.999	0.7539	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:25	RYTLDQQQFF	0.9989	0.863	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:15	RYTLDQQQFF	0.9983	0.8663	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:20	RYTLDQQQFF	0.9983	0.858	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:31	RYTLDQQQFF	0.9972	0.8544	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A23:05	RYTLDQQQFF	0.9937	0.6109	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B57:01	RYTLDQQQFF	0.9925	0.9892	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:17	RYTLDQQQFF	0.99	0.8007	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A23:04	RYTLDQQQFF	0.9889	0.5462	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:10	RYTLDQQQFF	0.9877	0.7614	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B38:01	HRYTLDQQQF	0.9821	0.9816	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B38:02	HRYTLDQQQF	0.9714	0.9812	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B58:02	RYTLDQQQFF	0.9712	0.9652	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B15:18	HRYTLDQQQF	0.9675	0.832	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A31:08	RYTLDQQQFF	0.9633	0.7151	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A23:04	HRYTLDQQQF	0.9605	0.7253	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:14	RYTLDQQQFF	0.9544	0.7776	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A32:13	RYTLDQQQFF	0.9399	0.9819	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A23:05	HRYTLDQQQF	0.9364	0.7769	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B57:03	RYTLDQQQFF	0.9355	0.9922	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:23	HRYTLDQQQF	0.9211	0.8341	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:25	HRYTLDQQQF	0.9115	0.9068	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:10	HRYTLDQQQF	0.8979	0.8471	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:20	HRYTLDQQQF	0.892	0.9037	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B15:16	RYTLDQQQFF	0.8856	0.9376	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:15	HRYTLDQQQF	0.8853	0.9059	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:31	HRYTLDQQQF	0.8701	0.8933	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B58:01	RYTLDQQQFF	0.862	0.9726	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B15:17	RYTLDQQQFF	0.8422	0.9566	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:17	HRYTLDQQQF	0.7395	0.8586	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B27:05	HRYTLDQQQFF	1	0.6965	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B27:04	HRYTLDQQQFF	1	0.7824	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B27:07	HRYTLDQQQFF	0.9999	0.8203	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A23:04	HRYTLDQQQFF	0.9958	0.6443	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:23	HRYTLDQQQFF	0.9955	0.835	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B57:03	HRYTLDQQQFF	0.9952	0.9863	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:23	VHRYTLDQQQF	0.9944	0.8407	9	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A23:04	VHRYTLDQQQF	0.9922	0.7423	9	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:25	VHRYTLDQQQF	0.9912	0.9286	9	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:10	VHRYTLDQQQF	0.9899	0.8523	9	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B38:01	VHRYTLDQQQF	0.9894	0.9537	9	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A23:05	VHRYTLDQQQF	0.9883	0.8034	9	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:20	VHRYTLDQQQF	0.9877	0.9258	9	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:15	VHRYTLDQQQF	0.9875	0.9303	9	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:31	VHRYTLDQQQF	0.9823	0.9056	9	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:17	VHRYTLDQQQF	0.9676	0.8659	9	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B15:18	HRYTLDQQQFF	0.9576	0.7964	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:14	VHRYTLDQQQF	0.9473	0.7828	9	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:23	RYTLDQQQFFT	0.8529	0.8901	11	22
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A23:04	RYTLDQQQFFT	0.6662	0.7928	11	22
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C15:04	RTLVHRYTL	0.9969	0.8634	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C03:08	YTLDQQQFF	0.9931	0.8863	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C15:06	RTLVHRYTL	0.9921	0.8672	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:02	RYTLDQQQF	0.9907	0.8734	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C03:19	YTLDQQQFF	0.9895	0.9808	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B27:14	HRYTLDQQQ	0.9884	0.7811	10	19
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C15:04	YTLDQQQFF	0.9869	0.8489	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B15:21	YTLDQQQFF	0.9819	0.9453	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C03:07	YTLDQQQFF	0.9788	0.9374	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C15:06	YTLDQQQFF	0.9747	0.8655	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A23:01	RYTLDQQQF	0.9657	0.7365	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B15:05	YTLDQQQFF	0.9552	0.8997	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C05:09	YTLDQQQFF	0.9552	0.9584	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B15:31	YTLDQQQFF	0.9494	0.9052	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:10	YTLDQQQFF	0.9451	0.9802	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C03:08	RTLVHRYTL	0.9441	0.8032	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:19	YTLDQQQFF	0.9378	0.9092	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:05	YTLDQQQFF	0.9298	0.9861	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:95	YTLDQQQFF	0.9244	0.91	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C03:14	YTLDQQQFF	0.9143	0.9605	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:27	YTLDQQQFF	0.9123	0.9817	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C12:16	YTLDQQQFF	0.8669	0.9881	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C04:06	YTLDQQQFF	0.8544	0.9545	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A01:02	YTLDQQQFF	0.8246	0.5703	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:19	RYTLDQQQF	0.733	0.8757	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C04:14	YTLDQQQFF	0.7081	0.9343	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C12:12	YTLDQQQFF	0.6579	0.9889	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:10	RYTLDQQQF	0.655	0.9843	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C08:04	YTLDQQQFF	0.6437	0.9736	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C08:13	YTLDQQQFF	0.6437	0.9736	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:67	RYTLDQQQF	0.6314	0.9754	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:80	RYTLDQQQF	0.6314	0.9754	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:27	RYTLDQQQF	0.6119	0.9817	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C12:04	YTLDQQQFF	0.5754	0.9972	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C06:03	YTLDQQQFF	0.5575	0.9978	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C08:03	YTLDQQQFF	0.5532	0.9911	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:46	RYTLDQQQF	0.4841	0.9382	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C02:06	YTLDQQQFF	0.1825	0.9163	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B27:14	HRYTLDQQQF	1	0.6943	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B27:03	HRYTLDQQQF	0.9994	0.6764	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:95	HRYTLDQQQF	0.9992	0.869	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:05	HRYTLDQQQF	0.9988	0.9792	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:02	RYTLDQQQFF	0.9983	0.858	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:27	HRYTLDQQQF	0.9971	0.9739	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:10	HRYTLDQQQF	0.996	0.9811	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:19	HRYTLDQQQF	0.9958	0.8667	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:46	HRYTLDQQQF	0.9919	0.938	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A23:01	RYTLDQQQFF	0.9915	0.6122	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:67	HRYTLDQQQF	0.9915	0.9673	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:80	HRYTLDQQQF	0.9915	0.9673	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B39:12	HRYTLDQQQF	0.9841	0.9574	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C12:16	HRYTLDQQQF	0.973	0.9872	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A23:01	HRYTLDQQQF	0.9046	0.7764	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:02	HRYTLDQQQF	0.892	0.9037	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B27:14	HRYTLDQQQFF	1	0.73	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:95	HRYTLDQQQFF	0.9999	0.8607	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:27	HRYTLDQQQFF	0.9998	0.9711	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:05	HRYTLDQQQFF	0.9998	0.9803	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B27:03	HRYTLDQQQFF	0.9992	0.7143	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:19	HRYTLDQQQFF	0.9991	0.8328	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:10	HRYTLDQQQFF	0.9987	0.9752	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:46	HRYTLDQQQFF	0.9984	0.9161	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:67	HRYTLDQQQFF	0.9981	0.9574	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:80	HRYTLDQQQFF	0.9981	0.9574	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:02	VHRYTLDQQQF	0.9877	0.9258	9	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A23:01	VHRYTLDQQQF	0.9839	0.8092	9	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C12:16	HRYTLDQQQFF	0.9826	0.9865	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C16:02	YTLDQQQF	0.9725	0.993	12	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C15:09	RTLVHRYTL	0.9969	0.8634	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B57:10	RTLVHRYTL	0.9955	0.9407	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C15:02	RTLVHRYTL	0.9946	0.7927	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C03:04	YTLDQQQFF	0.9946	0.9813	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C03:03	YTLDQQQFF	0.9946	0.9813	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C03:02	YTLDQQQFF	0.9941	0.9688	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:03	RYTLDQQQF	0.9931	0.7973	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A32:01	RTLVHRYTL	0.9928	0.7828	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C15:05	RTLVHRYTL	0.9927	0.8145	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C03:67	YTLDQQQFF	0.9924	0.9762	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B57:04	YTLDQQQFF	0.9919	0.7172	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B58:06	RTLVHRYTL	0.9896	0.6625	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C15:09	YTLDQQQFF	0.9869	0.8489	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B57:04	RTLVHRYTL	0.9852	0.694	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B58:06	YTLDQQQFF	0.9827	0.8917	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B57:02	YTLDQQQFF	0.981	0.9336	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B57:10	YTLDQQQFF	0.9791	0.9577	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B15:13	YTLDQQQFF	0.9747	0.7937	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C16:01	RTLVHRYTL	0.9739	0.9737	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A30:01	RTLVHRYTL	0.9706	0.7795	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B35:11	YTLDQQQFF	0.9685	0.9417	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:22	YTLDQQQFF	0.9644	0.9168	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C03:17	RTLVHRYTL	0.9638	0.8892	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C16:04	YTLDQQQFF	0.9611	0.9941	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B15:20	YTLDQQQFF	0.9602	0.9254	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C05:01	YTLDQQQFF	0.9552	0.9584	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C03:05	RTLVHRYTL	0.9546	0.7904	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C04:03	YTLDQQQFF	0.9537	0.9502	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C16:02	RTLVHRYTL	0.9528	0.9888	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B35:23	YTLDQQQFF	0.9512	0.9337	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:17	YTLDQQQFF	0.9511	0.9867	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C03:17	YTLDQQQFF	0.9448	0.9421	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C03:05	YTLDQQQFF	0.9428	0.8885	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B35:28	YTLDQQQFF	0.9357	0.9311	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C15:05	YTLDQQQFF	0.9242	0.898	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A25:01	YTLDQQQFF	0.9229	0.9632	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B15:11	YTLDQQQFF	0.918	0.8924	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B15:08	YTLDQQQFF	0.9162	0.8887	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:01	YTLDQQQFF	0.9145	0.8808	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B35:43	YTLDQQQFF	0.8968	0.8932	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B57:02	RTLVHRYTL	0.8958	0.8294	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B15:24	YTLDQQQFF	0.8898	0.9336	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C15:02	YTLDQQQFF	0.8866	0.8581	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C16:01	YTLDQQQFF	0.8726	0.9873	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A32:01	YTLDQQQFF	0.8654	0.9719	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C04:04	YTLDQQQFF	0.8075	0.9602	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C06:06	YTLDQQQFF	0.7961	0.9939	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C12:02	YTLDQQQFF	0.7877	0.9869	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C12:03	YTLDQQQFF	0.7729	0.9938	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C16:02	YTLDQQQFF	0.7067	0.9899	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C03:06	YTLDQQQFF	0.6946	0.9845	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:17	RYTLDQQQF	0.647	0.9857	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:02	RYTLDQQQF	0.6314	0.9754	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A30:04	YTLDQQQFF	0.5635	0.5143	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C08:01	YTLDQQQFF	0.5532	0.9911	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B53:02	YTLDQQQFF	0.4703	0.6344	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B07:13	RTLVHRYTL	0.2963	0.5983	6	15
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C02:10	YTLDQQQFF	0.2439	0.9547	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C02:02	YTLDQQQFF	0.2439	0.9547	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B51:06	YTLDQQQFF	0.2132	0.6318	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C17:01	YTLDQQQFF	0.1985	0.959	12	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C06:06	RYTLDQQQF	0.1123	0.9971	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C14:02	RYTLDQQQF	0.1094	0.9939	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C14:03	RYTLDQQQF	0.1094	0.9939	11	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B27:08	HRYTLDQQQF	1	0.571	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B27:10	HRYTLDQQQF	0.9999	0.8322	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B27:06	HRYTLDQQQF	0.9998	0.8114	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B27:09	HRYTLDQQQF	0.9998	0.6383	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:01	HRYTLDQQQF	0.9994	0.841	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:03	RYTLDQQQFF	0.999	0.7539	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:22	HRYTLDQQQF	0.9988	0.9053	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C06:08	HRYTLDQQQF	0.9981	0.9923	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B57:10	RYTLDQQQFF	0.9925	0.9892	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:02	HRYTLDQQQF	0.9915	0.9673	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B38:05	HRYTLDQQQF	0.9821	0.9816	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B57:04	RYTLDQQQFF	0.9817	0.8443	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B15:68	HRYTLDQQQF	0.9721	0.7946	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C06:17	HRYTLDQQQF	0.9699	0.9965	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C06:02	HRYTLDQQQF	0.9699	0.9965	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B58:06	RYTLDQQQFF	0.9664	0.9187	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B57:02	RYTLDQQQFF	0.9648	0.9824	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:03	HRYTLDQQQF	0.9211	0.8341	10	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A32:01	RYTLDQQQFF	0.9103	0.9814	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A30:04	RYTLDQQQFF	0.4743	0.7381	11	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B27:10	HRYTLDQQQFF	1	0.8451	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B27:09	HRYTLDQQQFF	1	0.6787	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B27:08	HRYTLDQQQFF	1	0.6248	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B27:06	HRYTLDQQQFF	1	0.8236	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:01	HRYTLDQQQFF	0.9999	0.8242	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:22	HRYTLDQQQFF	0.9994	0.908	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C06:08	HRYTLDQQQFF	0.9989	0.9908	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C07:02	HRYTLDQQQFF	0.9981	0.9574	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:03	HRYTLDQQQFF	0.9955	0.835	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:03	VHRYTLDQQQF	0.9944	0.8407	9	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B57:02	HRYTLDQQQFF	0.9915	0.9826	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B38:05	VHRYTLDQQQF	0.9894	0.9537	9	20
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-B57:04	HRYTLDQQQFF	0.9878	0.8667	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C06:02	HRYTLDQQQFF	0.9762	0.9962	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-C06:17	HRYTLDQQQFF	0.9762	0.9962	10	21
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	HLA-A24:03	RYTLDQQQFFT	0.8529	0.8901	11	22

Top

Potential FusionNeoAntigen Information of ATP11A-NUCB2 in HLA II

ATP11A-NUCB2_113344769_17351673.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB1-0305	VHRYTLDQQQFFTEE	9	24
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB1-0338	VHRYTLDQQQFFTEE	9	24
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB1-0338	LVHRYTLDQQQFFTE	8	23
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0101	VHRYTLDQQQFFTEE	9	24
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0101	LVHRYTLDQQQFFTE	8	23
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0101	HRYTLDQQQFFTEEE	10	25
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0101	TLVHRYTLDQQQFFT	7	22
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0104	VHRYTLDQQQFFTEE	9	24
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0104	LVHRYTLDQQQFFTE	8	23
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0104	HRYTLDQQQFFTEEE	10	25
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0104	TLVHRYTLDQQQFFT	7	22
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0105	VHRYTLDQQQFFTEE	9	24
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0105	LVHRYTLDQQQFFTE	8	23
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0105	HRYTLDQQQFFTEEE	10	25
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0105	TLVHRYTLDQQQFFT	7	22
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0108	VHRYTLDQQQFFTEE	9	24
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0108	LVHRYTLDQQQFFTE	8	23
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0108	HRYTLDQQQFFTEEE	10	25
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0108	TLVHRYTLDQQQFFT	7	22
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0109	VHRYTLDQQQFFTEE	9	24
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0109	LVHRYTLDQQQFFTE	8	23
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0111	VHRYTLDQQQFFTEE	9	24
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0111	LVHRYTLDQQQFFTE	8	23
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0111	HRYTLDQQQFFTEEE	10	25
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0111	TLVHRYTLDQQQFFT	7	22
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0112	VHRYTLDQQQFFTEE	9	24
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0112	LVHRYTLDQQQFFTE	8	23
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0112	HRYTLDQQQFFTEEE	10	25
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0112	TLVHRYTLDQQQFFT	7	22
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0113	VHRYTLDQQQFFTEE	9	24
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0113	LVHRYTLDQQQFFTE	8	23
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0113	HRYTLDQQQFFTEEE	10	25
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0113	TLVHRYTLDQQQFFT	7	22
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0114	VHRYTLDQQQFFTEE	9	24
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0114	LVHRYTLDQQQFFTE	8	23
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0114	HRYTLDQQQFFTEEE	10	25
ATP11A-NUCB2	chr13	113344769	chr11	17351673	127	DRB3-0114	TLVHRYTLDQQQFFT	7	22

Top

Fusion breakpoint peptide structures of ATP11A-NUCB2

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
8280	RTLVHRYTLDQQQF	ATP11A	NUCB2	chr13	113344769	chr11	17351673	127

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ATP11A-NUCB2

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	8280	RTLVHRYTLDQQQF	-7.15543	-7.26883
HLA-B14:02	3BVN	8280	RTLVHRYTLDQQQF	-4.77435	-5.80965
HLA-B52:01	3W39	8280	RTLVHRYTLDQQQF	-6.80875	-6.92215
HLA-B52:01	3W39	8280	RTLVHRYTLDQQQF	-4.20386	-5.23916
HLA-A11:01	4UQ2	8280	RTLVHRYTLDQQQF	-7.5194	-8.5547
HLA-A11:01	4UQ2	8280	RTLVHRYTLDQQQF	-6.9601	-7.0735
HLA-A24:02	5HGA	8280	RTLVHRYTLDQQQF	-7.52403	-7.63743
HLA-A24:02	5HGA	8280	RTLVHRYTLDQQQF	-5.82433	-6.85963
HLA-B27:05	6PYJ	8280	RTLVHRYTLDQQQF	-3.28285	-4.31815
HLA-B44:05	3DX8	8280	RTLVHRYTLDQQQF	-5.91172	-6.94702
HLA-B44:05	3DX8	8280	RTLVHRYTLDQQQF	-4.24346	-4.35686

Top

Vaccine Design for the FusionNeoAntigens of ATP11A-NUCB2

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
ATP11A-NUCB2	chr13	113344769	chr11	17351673	10	19	HRYTLDQQQ	CACAGATACACATTAGATCAGCAACAG
ATP11A-NUCB2	chr13	113344769	chr11	17351673	10	20	HRYTLDQQQF	CACAGATACACATTAGATCAGCAACAGTTC
ATP11A-NUCB2	chr13	113344769	chr11	17351673	10	21	HRYTLDQQQFF	CACAGATACACATTAGATCAGCAACAGTTCTTC
ATP11A-NUCB2	chr13	113344769	chr11	17351673	11	20	RYTLDQQQF	AGATACACATTAGATCAGCAACAGTTC
ATP11A-NUCB2	chr13	113344769	chr11	17351673	11	21	RYTLDQQQFF	AGATACACATTAGATCAGCAACAGTTCTTC
ATP11A-NUCB2	chr13	113344769	chr11	17351673	11	22	RYTLDQQQFFT	AGATACACATTAGATCAGCAACAGTTCTTCACA
ATP11A-NUCB2	chr13	113344769	chr11	17351673	12	20	YTLDQQQF	TACACATTAGATCAGCAACAGTTC
ATP11A-NUCB2	chr13	113344769	chr11	17351673	12	21	YTLDQQQFF	TACACATTAGATCAGCAACAGTTCTTC
ATP11A-NUCB2	chr13	113344769	chr11	17351673	6	15	RTLVHRYTL	CGGACGCTCGTGCACAGATACACATTA
ATP11A-NUCB2	chr13	113344769	chr11	17351673	9	20	VHRYTLDQQQF	GTGCACAGATACACATTAGATCAGCAACAGTTC

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
ATP11A-NUCB2	chr13	113344769	chr11	17351673	10	25	HRYTLDQQQFFTEEE	CACAGATACACATTAGATCAGCAACAGTTCTTCACAGAGGAAGAA
ATP11A-NUCB2	chr13	113344769	chr11	17351673	7	22	TLVHRYTLDQQQFFT	ACGCTCGTGCACAGATACACATTAGATCAGCAACAGTTCTTCACA
ATP11A-NUCB2	chr13	113344769	chr11	17351673	8	23	LVHRYTLDQQQFFTE	CTCGTGCACAGATACACATTAGATCAGCAACAGTTCTTCACAGAG
ATP11A-NUCB2	chr13	113344769	chr11	17351673	9	24	VHRYTLDQQQFFTEE	GTGCACAGATACACATTAGATCAGCAACAGTTCTTCACAGAGGAA

Top

Information of the samples that have these potential fusion neoantigens of ATP11A-NUCB2

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
OV	ATP11A-NUCB2	chr13	113344769	ENST00000283558	chr11	17351673	ENST00000323688	TCGA-29-2428

Top

Potential target of CAR-T therapy development for ATP11A-NUCB2

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to ATP11A-NUCB2

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to ATP11A-NUCB2

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)